Johnson & Johnson (JNJ) Earnings Per Share (EPS): 8.65
Is Johnson & Johnson’s earnings per share (EPS) high or low?
Johnson & Johnson's earnings per share (EPS) of 8.65 is in line with its 5-year average of 8.52, around the middle of its 5-year range (5.59–13.88).
The earnings per share (EPS) for Johnson & Johnson (JNJ) is 8.65 as of Wednesday, June 10, 2026. It is above its 12-month average by 2.55% (8.43).
JNJ Earnings Per Share (EPS) Chart
JNJ Average Earnings Per Share (EPS) Chart
JNJ Current vs Average Earnings Per Share (EPS) Chart
JNJ Earnings Per Share (EPS) Metrics
EARNINGS PER SHARE (EPS)
8.65
EARNINGS PER SHARE (EPS) AVG TTM
8.43
EARNINGS PER SHARE (EPS) AVG 3Y
9.39
EARNINGS PER SHARE (EPS) AVG 5Y
8.52
EARNINGS PER SHARE (EPS) AVG 10Y
6.79
EARNINGS PER SHARE (EPS) AVG 15Y
6.11
EARNINGS PER SHARE (EPS) AVG 20Y
5.61
CURRENT VS TTM AVG
+2.55%
CURRENT VS 3Y AVG
-7.93%
CURRENT VS 5Y AVG
+1.57%
CURRENT VS 10Y AVG
+27.34%
CURRENT VS 15Y AVG
+41.53%
CURRENT VS 20Y AVG
+54.31%
JNJ Competitors' Earnings Per Share (EPS)
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Johnson & Johnson (JNJ) | $574.15B | 8.65 | 8.43 | 9.39 | 8.52 |
| Pfizer Inc. (PFE) | $146.36B | 1.31 | 1.39 | 2.19 | 2.39 |
| Merck & Co., Inc. (MRK) | $293.02B | 3.55 | 7.03 | 4.98 | 4.65 |
| AbbVie Inc. (ABBV) | $399.54B | 2.04 | 2.38 | 3.54 | 3.89 |
| Eli Lilly and Company (LLY) | $1.07T | 28.15 | 17.38 | 11.79 | 9.91 |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 3.56 | -0.48 | 1.47 | 0.84 |
EPS Comparison
Trailing EPS (TTM)
$8.65
Forward EPS (Est.)
$12.77
P/E Ratio
27.6
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
- Directly impacts stock valuation through P/E ratio
- Used to calculate dividend coverage and payout ratios
- Enables comparison across companies of different sizes
- Growth in EPS often correlates with stock price appreciation
Johnson & Johnson Earnings Per Share (EPS) Formula & Definition
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Johnson & Johnson Earnings Per Share (EPS) FAQ
- What is the earnings per share (EPS) for Johnson & Johnson (JNJ)?
- The earnings per share (EPS) for JNJ stock is 8.65.
- Is Johnson & Johnson's earnings per share (EPS) high or low?
- Johnson & Johnson's earnings per share (EPS) of 8.65 is in line with its 5-year average of 8.52, around the middle of its 5-year range (5.59–13.88).
- What is the TTM average earnings per share (EPS) for Johnson & Johnson (JNJ)?
- The TTM average earnings per share (EPS) for JNJ stock is 8.43.
- What is the 3Y average earnings per share (EPS) for Johnson & Johnson (JNJ)?
- The 3Y average earnings per share (EPS) for JNJ stock is 9.39.
- What is the 5Y average earnings per share (EPS) for Johnson & Johnson (JNJ)?
- The 5Y average earnings per share (EPS) for JNJ stock is 8.52.
- What is the 10Y average earnings per share (EPS) for Johnson & Johnson (JNJ)?
- The 10Y average earnings per share (EPS) for JNJ stock is 6.79.
- What is the 15Y average earnings per share (EPS) for Johnson & Johnson (JNJ)?
- The 15Y average earnings per share (EPS) for JNJ stock is 6.11.
- What is the 20Y average earnings per share (EPS) for Johnson & Johnson (JNJ)?
- The 20Y average earnings per share (EPS) for JNJ stock is 5.61.
Johnson & Johnson Earnings Per Share (EPS) History
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-28 | 11.03 |
| 2024-12-29 | 5.84 |
| 2023-12-31 | 13.88 |
| 2023-01-01 | 6.83 |
| 2022-01-02 | 7.93 |
| 2021-01-03 | 5.59 |
| 2019-12-31 | 5.74 |
| 2018-12-31 | 5.75 |
| 2017-12-31 | 0.48 |
| 2016-12-31 | 6.08 |
| 2015-12-31 | 5.57 |
| 2014-12-31 | 5.86 |
| 2013-12-31 | 4.90 |
| 2012-12-31 | 3.91 |
| 2011-12-31 | 3.54 |
| 2010-12-31 | 4.86 |
| 2009-12-31 | 4.45 |
| 2008-12-31 | 4.67 |
| 2007-12-31 | 3.67 |
| 2006-12-31 | 3.76 |
| 2005-12-31 | 3.38 |
| 2004-12-31 | 2.75 |
| 2003-12-31 | 2.42 |
| 2002-12-31 | 2.20 |
| 2001-12-31 | 1.87 |
| 2000-12-31 | 1.65 |
| 1999-12-31 | 1.43 |
| 1998-12-31 | 1.08 |
| 1997-12-31 | 1.24 |
| 1996-12-31 | 1.09 |
Related Metrics
About Johnson & Johnson
Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Joaquin Duato